Outcasted · board guidelines & rules chat help search members calendar outcasted forums life drugs & alcohol pages: 2 ; 2 go first unread post ; robotussin , sounds like fun : ; track this topic email this topic print this topic posted: aug 21 2005, member group: members 245 member no: 1152 joined: 20-march 05 so i know its a pill and everything but what are the effects how long does it stay in your system and all the rest, for instance, finasteride forum. Dht dihydrotestosterone ; - finasteride proscar ; , a drug that blocks the enzyme named 5-alpha-reductase, which changes testosterone to dihydrotestosterone.

Hormone or androgen suppression the drug proscar, or finasteride, suppresses the action of the hormone testosterone in the prostate cells without affecting the level of testosterone in the blood stream and itraconazole.
Many technology companies Cisco, Microsoft, Novell, among others ; have been widely successful developing and maintaining an ecosystem of certified professionals. These companies have provided these professionals with a clear-cut, replicable and demonstrable model for financial and professional success. I propose that, through an alliance between PHI and global organizations such as the WHO ; , we should develop an equivalent certification program for Health Engineers. This is geared towards enabling technology-savvy users to become health engineers by providing them with the proper "package" of tools, knowledge, and support services to allow those users to become health change agents in their communities. As stated above, we can talk about the need and the opportunity as well ; to qualify those already inclined towards health knowledge and to turn them into recognized professionals. With a global institution such as the WHO ; providing the guidance, PHI volunteers can develop both the technical and educational training, as well as the enabling IT-centric tools, for Health Engineers to perform their duties in a professional and standardized way. Does the world really need more health professionals? According to the World Health Organization, the answer is a resounding yes. The shortage of health workers with the right expertise and experience has reached crisis levels in Less-Developed Countries. The ability of health services to deliver care depends on the knowledge, skills and motivation of health workers. Without enough skilled staff in the right place at the right time health systems cannot function effectively and populations are left without needed treatment, support.36.

Study where hypospadias were present in male rats exposed in utero to 25 mg kg day through to 320 mg kg day dinasteride Imperato-McGinley et al., 1992 ; . Prenatal exposure to finasteride induced a dose-dependent increase in the incidence of ectopic testes with a single occurrence in the 1 mg kg day dose group and 73% of individuals affected in the 100 mg kg day dose group Fig. 5 ; . The high incidence of testicular maldescent in this study was an unexpected observation, since previous studies using similar dosing windows found little to no effect on testicular descent Clark et al., 1990 ; and others reported a relatively low incidence of undescended testes 8 to 27% ; Imperato-McGinley et al., 1992; Spencer et al., 1991 ; . A possible explanation for the. Based on the observations that androgens are necessary for the development of prostate cancer and that men with a congenital deficiency of the 5--reductase type 2 enzyme do not develop prostate cancer, a 7-year randomised, controlled trial with the drug finasteride was undertaken with 18 882 men who were 55 years, had a normal prostate on digital rectal examination and a PSA of 3 ng ml. The study was ended 15 months prematurely because the end-point had been reached and continuing the trial would not have changed the outcome. Men who received finasteride, which inhibits conversion of testosterone to dihydrotestosterone DHT ; by targeting the 5--reductase type 2 enzyme, had a prostate cancer prevalence reduction of 24.8% 24.4% to 18.4%. However, the prevalence of Gleason 7-10 tumours was higher in the finasteride arm 6.4% versus 5.1% ; although 98% of the tumours were clinically localised. 204 ; . Klein et al 2005 ; 205 ; have questioned the validity of the conclusion in relation to the rate of clinically-significant prostate cancer detection in this trial. They present a model of risk and benefit that estimates the potential influence of histological artefact due to finasteride-induced effect on prostatic epithelial appearances ; in the assignment of excess risk for high-grade disease and possible overdetection bias introduced by finasteride-induced volume reduction in prostates for the treated patients 205 ; . A further industry-sponsored study, the REDUCE Reduction by DUtasteride in prostate cancer Events ; trial is in progress. In this randomised, controlled study involving 8 000 men with PSA values between 2 and 10 ng ml dutasteride, which inhibits both isoforms of the 5--reductase enzyme, is being used in the treatment arm. All patients in this trial are being biopsied at least twice during the study unlike the finasteride study in which prostatic biopsies were recommended if the annual PSA adjusted for the effect of finasteride ; exceeded 4 ng ml the digital rectal examination was abnormal. Recent research suggests that inhibition of the irreversible action of 5-reductase to convert testosterone to the more transcriptionally active dihydrotestosterone may have untoward effects in relation to prostate cancer. Dihydrotestosterone in turn is hydroxylated to 3-diol and 3-Adiol which do not bind to the androgen receptor but have a strong affinity for oestrogen receptors, the result of which is thought to have a direct effect on prostate development and homeostasis 206 ; . The binding of 3-Adiol to oestrogen receptor beta ER ; induces expression of the cell adhesion molecule E-cadherin, loss of which is associated with a more aggressive phenotype in prostate cancer cells 38. 1. Cookson J, Crammer J, Heine B. A n drugs and hypnotics. In: The use of drugs in psychiatry. 4th ed. London: Gaskell, 1993: 269-81. 2. Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988; 49: 1848. American Psychiatric Association. Physiological dependence on benzodiazepine. In: Benzodiazepine dependence, toxicity, and abuse. Washington: American Psychiatric Association, 1990: 15-23. 4. Hong Kong Government Census and Statistics Department. Annual Digest of Statistics, 1991-1994. Hong Kong, 1995. 5. British Medical Association and Royal Pharmaceutical Society of Great Britain. Hypnotics and anxiolytics. In: Prasad AB, editor. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, 1995: 14552. 6. Lee KK, Chan TY, Chan AW, et al. Use and abuse of benzodiazepines in Hong Kong, 1990-1993--the impact of regulatory changes. J Toxicol Clin Toxicol 1995; 33: 597-602. Weintraub M, Singh S, Byrne L, et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991 ; 226: 2392-7. 8. Baiter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992; 53 12 Suppl ; : 34S-39S. 9. Dunbar GC, Perera HM, Jenner FA. Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 1989: 155: 836-41. Wysowski DK, Barash D. Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's spontaneous reporting system. Arch Intern Med 1991; 151: 2003-8. Cooper SJ. Anxiolytics, sedatives, hypnotics. In: King DJ, editor. Seminars in clinical psychopharmacology. London: Gaskell, 1995: 103-37. 12. Martin Arias LH, Carvajal A, De Diego IM, De Abajo F. Before and after triazolam: changes in the consumption of hypnotics in Spain. Br J Clin Pharmacol 1995; 40: 287-90. Mendelson WB. Long-term follow-up of chronic insomnia. Sleep 1995; 18: 698-101. Transient hypotensive response is not a contraindication to further doses of CARDURA doxazosin mesylate ; . Information for Patients See patient package insert ; : Patients should be made aware of the possibility of syncopal and orthostatic symptoms, especially at the initiation of therapy, and urged to avoid driving or hazardous tasks for 24 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. They should be cautioned to avoid situations where injury could result should syncope occur during initiation of doxazosin therapy. They should also be advised of the need to sit or lie down when symptoms of lowered blood pressure occur, although these symptoms are not always orthostatic, and to be careful when rising from a sitting or lying position. If dizziness, lightheadedness, or palpitations are bothersome they should be reported to the physician, so that dose adjustment can be considered. Patients should also be told that drowsiness or somnolence can occur with CARDURA doxazosin mesylate ; or any selective alpha1 adrenoceptor antagonist, requiring caution in people who must drive or operate heavy machinery. Patients should be advised about the possibility of priapism as a result of treatment with alpha1 antagonists. Patients should know that this adverse event is very rare. If they experience priapism, it should be brought to immediate medical attention for if not treated promptly it can lead to permanent erectile dysfunction impotence ; . Drug Laboratory Test Interactions: CARDURA does not affect the plasma concentration of prostate specific antigen in patients treated for up to 3 years. Both doxazosin, an alpha1 inhibitor, and finasteride, a 5-alpha reductase inhibitor, are highly protein bound and hepatically metabolized. There is no definitive controlled clinical experience on the concomitant use of alpha1 inhibitors and 5-alpha reductase inhibitors at this time. Impaired Liver Function: CARDURA should be administered with caution to patients with evidence of impaired hepatic function or to patients receiving drugs known to influence hepatic metabolism see CLINICAL PHARMACOLOGY ; . Leukopenia Neutropenia: Analysis of hematologic data from hypertensive patients receiving CARDURA in controlled hypertension clinical trials showed that the mean WBC N 474 ; and mean neutrophil counts N 419 ; were decreased by 2.4% and 1.0%, respectively, compared to placebo, a phenomenon seen with other alpha blocking drugs. In BPH patients the incidence of clinically significant WBC abnormalities was 0.4% 2 459 ; with CARDURA and 0% 0 147 ; with placebo, with no statistically significant difference between the two treatment groups. A search through a data base of 2400 hypertensive patients and 665 BPH patients revealed 4 hypertensives in which drug-related neutropenia could not be ruled out and one BPH patient in which drug related leukopenia could not be ruled out. Two hypertensives had a single low value on the last day of treatment. Two hypertensives had stable, non-progressive neutrophil counts in the 1000 mm3 range over periods of 20 and 40 weeks. One BPH patient had a decrease from a WBC count of 4800 mm3 to 2700 mm3 at the end of the study; there was no evidence of clinical impairment. In cases where follow-up was available the WBCs and neutrophil counts returned to.

Again. A patient who developed severe muscle cramps on the sixth day stopped the drug after the eighth day; the cramps continued for three more days. The patient with severe hemophilia A developed a marked generalized pruritic maculopapular rash on the eighth day of treatment day. The tionable developed and patient discontinued with mild the hemophilia drug after who had the tenth a ques.

Receptor in various target tissues. Molecular and Cellular Endocrinology 1986 44 261 Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone P et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2000 85 89 Muderris II, Bayram F, Sahin Y, Kelestimur F, Tutus A & Ayata D. The efficacy of 250 mg day flutamide in the treatment of patients with hirsutism. Fertility and Sterility 1996 66 220222. Muderris II, Bayram F & Guven M. A prospective, randomized trial comparing flutamide 250 mg day ; and finasteride 5 mg day ; in the treatment of hirsutism. Fertility and Sterility 2000 73 984 Bayram F, Muderris II, Sahin Y & Kelestimur F. Vinasteride treat ment for one year in 35 hirsute patients. Experimental and Clinical Endocrinology and Diabetes 1999 107 195 Crosby PDA & Rittmaster RS. Predictors of clinical response in hirsute women treated with spironolactone. Fertility and Sterility 1991 55 10761081. Wong IL, Morris RS, Chang L, Spahn M, Stanczyk FZ & Lobo R. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. Journal of Clinical Endocrinology and Metabolism 1995 80 223238. Castello R, Tosi F, Perrone F, Negri C, Muggeo M & Moghetti P. Outcome of long term treatment with the 5a-reductase inhibitor of finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertility and Sterility 1996 66 734740. Sahin Y, Bayram F, Kelestimur F & Muderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. Journal of Endocrinological Investigation 1998 21 348 Bayram F, Muderris I, Guven M & Kelestimur F. Comparison of high-dose finasteride 5 mg day ; versus low-dose finasteride 2.5 mg day ; in the treatment of hirsutism. European Journal of Endocrinology 2002 147 467471. Lobo RA, Shoupe D, Serafini P, Brinton D & Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertility and Sterility 1985 43 200 Carmina E & Lobo RA. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstetrics and Gynecology 1991 78 845 Schriock EA & Schriock ED. Treatment of hirsutism. Clinical Obstetrics and Gynecology 1991 34 852. According to the results of a study done by the southwest oncology group in san francisco, the drug that is sold by merck & co under the brand name of proscar finasteride ; is both more effective in preventing prostate cancer but is also potentially more dangerous than expected!

Meta-analyses of RCT data found that treatment with finasteride was not associated with an increased rate of symptomatic postural hypotension compared with placebo. The combination of terazosin finasteride but not of doxazosin finasteride was associated with a statistically significantly increased risk of the condition; in each case, however, these results were based on data from single studies and therefore should be viewed as preliminary. No RCTs reported on this outcome for alfuzosin finasteride.

Buy finasteride 5mg The Japanese market for prescription products remained sluggish. Net sales of our prescription products increased by 16 % in local currency by 7 % in euro terms ; and by the end of the year our market share reached 1.7 %, despite a governmentimposed price cut in April, averaging 5.6 % for our business. Australia, our second most important AAA market, achieved net sales of EUR 118 million and market share of over 2.3 %. We achieved significant sales and established a respectable market share of 1.5 % in Turkey, making it our third most important country in the AAA region. In South Korea, where we have a joint venture with a local partner, sales growth exceeded 24 %. Here we closely follow ongoing governmental deliberations on positive listing for drug. Proscar is finasteride in a 5mg dosage. Pharmacy Network: Can I use the same pharmacy I have been going to?.

Finasteride alopecia dosage Finasteride tablets for sale Bedwetting briefs, immunoglobulin levels in infants, onchocerciasis sudan, afferent neurons and range just want love ya. Condition damaged hair, alzheimer's disease occupational therapy, leucovorin dilution and high altitude diabetes or neonatology questions. Finasteride prostate cancer prevention Finasteride indications, finasteride testicular pain, buying finasteride in the uk, buy finasteride for cheap and finasteride 90. Finaeteride side effects proscar, finasteride propecia�, buy finasteride 5mg and finasteride alopecia dosage or finasteride tablets for sale. © 2005-2008 Spo.orgfree.com, Inc. All rights reserved.